Brief: MedinCell Confirms Safety Of Continuous Administration of Ivermectin

Medincell SA

19/04/2021 16:54

April 19 (Reuters) - MEDINCELL SA  MEDCL.PA :
    * CLINICAL TRIAL CONDUCTED BY MEDINCELL CONFIRMS THE SAFETY
OF
CONTINUOUS ADMINISTRATION OF IVERMECTIN
    * NO SIDE EFFECTS WERE OBSERVED WITH THREE DOSES OF
IVERMECTIN
TESTED UP TO 100 ΜG / KG
    * POSITIVE RESULTS OF SAFETY STUDY
    * MEDINCELL DEVELOPS SEVERAL LONG-ACTING INJECTABLE
FORMULATIONS
OF IVERMECTIN, MOST ADVANCED AIMS AT PREVENTING INFECTION FROM
COVID-19 AND ITS MUTANTS FOR SEVERAL MONTHS
    * PROVING SAFETY OF IVERMECTIN IN REGULAR DAILY
ADMINISTRATION
OVER A LONG PERIOD WAS AN ESSENTIAL STEP FOR OUR IVERMECTIN
PROGRAMS, IN PARTICULAR MDC-TTG IN COVID-19-CHIEF DEVELOPMENT
OFFICER

Source text for Eikon:  ID:nBw1WrqC1a 
Further company coverage:  MEDCL.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))